Abstract: The present invention relates to peptides comprising at least one CD4+ T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4+ T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.

Abstract: The present invention relates to peptides comprising at least one CD4+ T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4+ T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.

Abstract: The present invention relates to peptides comprising at least one CD4+ T epitope, which is immunodominant in vitro, of the cyclin B1 tumor antigen, said peptides being capable of stimulating a specific human CD4+ T lymphocyte response in subjects who have varied HLA II molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin B1 during cancer or during an anticancer treatment.

Abstract: A method of selecting a test molecule that binds to HLA-DP4 by (i) incubating HLA-DP4 with the test molecule and a labeled peptide of formula (I) Z1X1X2X3X4X5X6X7X8X9Z2 thereby forming respective complexes, wherein Z1 and Z2, which may be identical or different, are each either zero or from 1 to 100 amino acids; X1 is an aromatic or hydrophobic amino acid, or S; X6 is an aromatic or hydrophobic amino acid, or C; X9 is an aromatic or hydrophobic amino acid, or C, D, Q, S, T, or E; and X2, X3, X4, X5, X7 and X8 are each an amino acid; (ii) separating the respective complexes formed; (iii) detecting the HLA-DP4/labeled peptide complexes; and (iv) selecting the test molecule that exhibits a binding activity of IC50<1000 nM, which corresponds to the concentration of the test molecule that inhibits 50% of the competitive HLA-DP4 binding of the labeled peptide.

Abstract: A method of selecting a test molecule that binds to HLA-DP4 by (i) incubating HLA-DP4 with the test molecule and a labeled peptide of formula (I) Z1X1X2X3X4X5X6X7X8X9Z2 thereby forming respective complexes, wherein Z1 and Z2, which may be identical or different, are each either zero or from 1 to 100 amino acids; X1 is an aromatic or hydrophobic amino acid, or S; X6 is an aromatic or hydrophobic amino acid, or C; X9 is an aromatic or hydrophobic amino acid, or C, D, Q, S, T, or E; and X2, X3, X4, X5, X7and X8 are each an amino acid; (ii) separating the respective complexes formed; (iii) detecting the HLA-DP4/labeled peptide complexes; and (iv) selecting the test molecule that exhibits a binding activity of IC50<1000 nM, which corresponds to the concentration of the test molecule that inhibits 50% of the competitive HLA-DP4 binding of the labeled peptide.

Abstract: The invention relates to a peptide mixture including at least two different peptides from the hepatitis C virus (HCV), whereby at least one of them is a peptide from the C protein binding to at least four different HLA-II molecules, the occurrence of which exceeds 5% in the Caucasian population with a binding activity <1,000 nM. Said invention also relates to the applications thereof as a drug useful in the prevention and treatment of HCV infections or as a diagnostic reagent for HCV-specific T lymphocytes.

Abstract: The invention relates to a method of selecting HLA-DP4 ligand molecules comprising the following steps: (i) incubation of purified HLA-DP4 with a tracer having general formula (I) Z1X1X2X3X4X5X6X7X8X9Z2 (wherein Z1 and Z2, which may be identical or different, are equal to zero or each represent a peptide with between 1 and 100 amino acids; X6 represents an aromatic or hydrophobic amino acid or a cysteine; and X1 represents an aromatic or hydrophobic amino acid and/or X9 represents an aromatic or hydrophobic amino acid or C, D, Q, S, T or E; and X2,X3,X4,X5,X7 and X8 each represent an amino acid) in the presence of different concentrations of molecule(s) to be tested; (ii) separation of the different complexes formed; (iii) detection of HLA-DP4/peptide tracer complexes; and (iv) selection of ligand molecules having a binding capacity IC50<1000 nM. The invention also relates to the applications of same.